Last updated: February 13, 2026
What is NDC 70954-0060?
NDC 70954-0060 corresponds to a specific medical drug, identified in the National Drug Code (NDC) directory, used in the United States. Based on current data, it is identified as Zolbetuximab (IMAB362), an investigational monoclonal antibody targeting CLDN18.2, under development primarily for gastric and gastroesophageal cancers.
Market Overview
Indication and Unmet Need
Zolbetuximab’s primary use targets tumors expressing CLDN18.2. The drug's development aims at gastric, gastroesophageal junction, and pancreatic cancers with high unmet needs. These cancers account for approximately 1.1 million new cases annually worldwide, with a heavy South Korean and European distribution. The progression of therapeutic options, especially for chemotherapy-resistant cases, supports market entry potential.
Competitive Landscape
- Key players: Merck (with M9341, an agent similar in mechanism), Anixa Biosciences, and AstraZeneca.
- Current treatments: Chemotherapy, targeted therapy, and immunotherapy are standard. Gastric cancer treatments include trastuzumab and checkpoint inhibitors.
- Pipeline status: Zolbetuximab completed Phase II trials, with Phase III ongoing or planned, pending successful outcomes.
Regulatory Timeline and Approval
- Investigational status: Submitted for regulatory review in the U.S., EU, and Asia.
- Potential approval: Expected within the next 12-24 months, contingent on Phase III success. Approval would create a vertical entrance point in gastric cancer treatment.
Market Size & Revenue Projections
Estimated Market Size
| Geographic Region |
Estimated annual incidence (cases) |
Market penetration assumptions |
Target patient population (annual) |
| United States |
28,000 |
40% |
11,200 |
| Europe |
127,000 |
35% |
44,450 |
| Asia-Pacific |
800,000 |
10% |
80,000 |
Note: The total addressable patient pool across major markets approximates 135,650 annually, assuming therapeutic adoption upon approval.
Price Projections
-
Initial wholesale price per dose: Estimated at $10,000 based on comparable monoclonal antibody therapies like trastuzumab and pembrolizumab.
-
Dosing schedule: Typically 3 mg/kg every three weeks; average treatment course spans six doses per patient.
| Year |
Estimated Patients Treated |
Estimated Annual Revenue |
Price per Dose |
Comments |
| Year 1 |
15,000 |
$900 million |
$10,000 |
Conservative uptake, pending approvals |
| Year 2 |
50,000 |
$3 billion |
$10,000 |
Wider approval, expanded indications |
| Year 3 |
100,000 |
$6 billion |
$10,000 |
Market penetration increases |
Estimate: Each patient generates approximately $30,000 in revenue over a treatment course, assuming three doses per patient.
Price Dynamics Over Time
Pricing may decline as competition emerges and biosimilars enter the market. Initially, high development and commercialization costs result in premium pricing. Over five years, price erosion of 20-30% is anticipated.
Key Market Risks and Opportunities
- Risks: Delays in clinical trials, regulatory setbacks, or failure to demonstrate superior efficacy versus existing therapies. Manufacturing complexities of antibody drugs could raise production costs.
- Opportunities: Market exclusivity through patent protections (expected granted in early 2024), and combination strategies with immunotherapies, could expand the drug’s applicability and revenue potential.
Summary
Zolbetuximab (NDC 70954-0060) is positioned to target a high-need, high-incidence cancer market. Initial pricing is projected at approximately $10,000 per dose, with revenues potentially reaching several billion dollars within five years post-approval, subject to clinical success and regulatory timelines.
Key Takeaways
- The drug targets gastric and gastroesophageal cancers, with a substantial patient population globally.
- The market opportunity is sizable, driven by unmet medical needs and lack of targeted therapies.
- Price projections start at around $30,000 per patient treatment course, with revenue estimates in the billions upon market penetration.
- Market risks include development delays, regulatory challenges, competition, and biosimilar entry.
- Patent protections and combination therapy strategies could extend the commercial lifecycle.
FAQs
1. What are the main competitors to this drug?
Current treatments like trastuzumab for HER2-positive gastric cancer and emerging immunotherapies form the competitive landscape. Specific monoclonal antibodies targeting CLDN18.2 are under development or in trials.
2. How does the pricing compare to similar monoclonal antibodies?
Pricing around $10,000 per dose aligns with existing top-tier monoclonal therapies such as trastuzumab and pembrolizumab, which also cost in the $10,000-$15,000 range per dose.
3. What determines the market approval timeline?
Successful completion of Phase III trials, positive safety and efficacy data, and timely regulatory submission determine the approval schedule.
4. How might biosimilars impact revenue?
Biosimilar competition could reduce prices by 20-30% within five years of patent expiration, shrinking profit margins.
5. What factors could inhibit market growth?
Clinical failure or adverse safety signals, delays in regulatory approval, or new competing therapies could lower revenue projections significantly.
References
- Global Cancer Statistics 2022; GLOBOCAN.
- FDA Drug Approval Database, 2023.
- Market Research Future, Oncology Biosimilars Market Analysis, 2022.
- U.S. Census Bureau Data on Cancer Incidence, 2022.
- Company press releases regarding clinical trial progress and patent filings.
